Saphetor Revenue and Competitors

Lausanne,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Saphetor's estimated annual revenue is currently $13.5M per year.(i)
  • Saphetor's estimated revenue per employee is $155,000

Employee Data

  • Saphetor has 87 Employees.(i)
  • Saphetor grew their employee count by 43% last year.

Saphetor's People

NameTitleEmail/Phone
1
Head RAQAReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
Senior Project ManagerReveal Email/Phone
4
Genomics Software Lead Product ManagerReveal Email/Phone
5
Senior Software EngineerReveal Email/Phone
6
Business Development ManagerReveal Email/Phone
7
Production Support Team LeadReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Saphetor?

Saphetor SA is a precision medicine company based in Switzerland whose goal is to improve outcomes for patients by offering clinicians data-driven solutions for making faster, more accurate diagnoses and for selecting the best therapies. Saphetor Platform is a clinically certified tool for variant discovery, annotation, and interpretation of next-generation DNA sequencing data for whole genomes, exomes, and gene panels, for individual samples, trios, families, and cohorts. Our platform empowers hundreds of clinicians, molecular geneticists and researchers by providing a feature-rich, validated and clinically certified tool that facilitates accurate diagnosis of diseases that had previously been difficult to identify. Visit our website and ask for 30-day FREE trial version!

keywords:N/A

N/A

Total Funding

87

Number of Employees

$13.5M

Revenue (est)

43%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A9445%N/A
#2
N/A9965%N/A
#3
$12.9M9938%N/A
#4
$14.5M100-2%N/A
#5
$16.1M1112%N/A